905 related articles for article (PubMed ID: 32529515)
21. Controversies in lymphoma: the role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma.
Dreger P; Laport GG
Biol Blood Marrow Transplant; 2008 Jan; 14(1 Suppl 1):100-7. PubMed ID: 18162229
[TBL] [Abstract][Full Text] [Related]
22. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.
Kharfan-Dabaja MA; Kumar A; Ayala E; Hamadani M; Reimer P; Gisselbrecht C; d'Amore F; Jantunen E; Ishida T; Bazarbachi A; Foss F; Advani R; Fenske TS; Lazarus HM; Friedberg JW; Aljurf M; Sokol L; Tobinai K; Tse E; Burns LJ; Chavez JC; Reddy NM; Suzuki R; Ahmed S; Nademanee A; Mohty M; Gopal AK; Fanale MA; Pro B; Moskowitz AJ; Sureda A; Perales MA; Carpenter PA; Savani BN
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1826-1838. PubMed ID: 28797780
[TBL] [Abstract][Full Text] [Related]
23. High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors.
Nademanee A; Palmer JM; Popplewell L; Tsai NC; Delioukina M; Gaal K; Cai JL; Kogut N; Forman SJ
Biol Blood Marrow Transplant; 2011 Oct; 17(10):1481-9. PubMed ID: 21338704
[TBL] [Abstract][Full Text] [Related]
24. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience.
Chen AI; McMillan A; Negrin RS; Horning SJ; Laport GG
Biol Blood Marrow Transplant; 2008 Jul; 14(7):741-7. PubMed ID: 18541192
[TBL] [Abstract][Full Text] [Related]
25. Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL.
Kameda K; Kako S; Kim SW; Usui Y; Kato K; Fukuda T; Uchida N; Kobayashi H; Wakayama T; Sakaida E; Yano S; Imada K; Nara M; Ikeda T; Fuchida SI; Ishikawa J; Sugahara H; Kanda J; Kimura T; Ichinohe T; Atsuta Y; Kondo E
Leukemia; 2022 May; 36(5):1361-1370. PubMed ID: 35347237
[TBL] [Abstract][Full Text] [Related]
26. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
Othman T; Herrera A; Mei M
Curr Hematol Malig Rep; 2021 Feb; 16(1):1-7. PubMed ID: 33409966
[TBL] [Abstract][Full Text] [Related]
27. Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin.
Nizamuddin I; Galvez C; Pro B
Semin Hematol; 2021 Apr; 58(2):85-94. PubMed ID: 33906726
[TBL] [Abstract][Full Text] [Related]
28. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
Abramson JS; Feldman T; Kroll-Desrosiers AR; Muffly LS; Winer E; Flowers CR; Lansigan F; Nabhan C; Nastoupil LJ; Nath R; Goy A; Castillo JJ; Jagadeesh D; Woda B; Rosen ST; Smith SM; Evens AM
Ann Oncol; 2014 Nov; 25(11):2211-2217. PubMed ID: 25193992
[TBL] [Abstract][Full Text] [Related]
29. Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy.
Burke JM; Liu N; Yu KS; Fanale MA; Surinach A; Flores C; Lisano J; Phillips T
Oncologist; 2023 Jun; 28(6):520-530. PubMed ID: 36971492
[TBL] [Abstract][Full Text] [Related]
30. Management of Peripheral T-cell Lymphomas and the Role of Transplant.
Foley NC; Mehta-Shah N
Curr Oncol Rep; 2022 Nov; 24(11):1489-1499. PubMed ID: 35947286
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada.
Zou D; Lee J; Kansal A; Ma W; Harris M; Lisano J; Fenton K; Yu KS
J Med Econ; 2022; 25(1):324-333. PubMed ID: 35172685
[TBL] [Abstract][Full Text] [Related]
32. Consolidation therapy with autologous stem cell transplantation after remission of induction chemotherapy prolongs the survival of patients with peripheral T-cell lymphoma.
Fulati W; Ma J; Wu M; Qian W; Chen P; Hu Y; Chen M; Xu Y; Huang Z; Zhang H; Xie Y; Shen L
Front Immunol; 2024; 15():1382189. PubMed ID: 38799461
[TBL] [Abstract][Full Text] [Related]
33. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
Zain JM
Am J Hematol; 2019 Aug; 94(8):929-946. PubMed ID: 31119775
[TBL] [Abstract][Full Text] [Related]
34. Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas.
Yam C; Landsburg DJ; Nead KT; Lin X; Mato AR; Svoboda J; Loren AW; Frey NV; Stadtmauer EA; Porter DL; Schuster SJ; Nasta SD
Am J Hematol; 2016 Jul; 91(7):672-6. PubMed ID: 27012928
[TBL] [Abstract][Full Text] [Related]
35. The clinical and economic burden of peripheral T-cell lymphoma: a systematic literature review.
Ashaye AO; Burnett H; Abogunrin S; Panchmatia H; Ovcinnikova O; Dalal M
Future Oncol; 2022 Feb; 18(4):519-535. PubMed ID: 34851173
[TBL] [Abstract][Full Text] [Related]
36. Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experience.
Han X; Zhang W; Zhou D; Ruan J; Duan M; Zhu T; Li J; Cai H; Cao X; Ouyang M
J Int Med Res; 2017 Feb; 45(1):290-302. PubMed ID: 28222648
[TBL] [Abstract][Full Text] [Related]
37. Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
Wagner SM; Melchardt T; Egle A; Magnes T; Skrabs C; Staber P; Simonitsch-Klupp I; Panny M; Lehner B; Greil R; Keil F; Jäger U; Sillaber C
Eur J Haematol; 2020 Mar; 104(3):251-258. PubMed ID: 31838747
[TBL] [Abstract][Full Text] [Related]
38. Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL.
Liu W; Wu J; Ming X; Zhang Q; Zhou D; Zheng R; Zhou M; Shang Z; Chen L; Zhu X; Xiao Y
Front Immunol; 2024; 15():1346001. PubMed ID: 38375471
[TBL] [Abstract][Full Text] [Related]
39. Current Treatment of Peripheral T-cell Lymphoma.
Stuver R; Epstein-Peterson ZD; Johnson WT; Khan N; Lewis N; Moskowitz AJ; Sauter CS; Horwitz S
Oncology (Williston Park); 2022 May; 36(5):293-305. PubMed ID: 35576176
[TBL] [Abstract][Full Text] [Related]
40. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas.
Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S
Crit Rev Oncol Hematol; 2016 Mar; 99():214-27. PubMed ID: 26811013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]